Health-related quality-of-life outcomes from a phase II open-label trial of two different starting doses of lenvatinib in combination with everolimus for treatment of renal cell carcinoma following one prior VEGF-targeted treatment.

Cristiane Decat Bergerot, Javier Puente, Sumanta K. Pal et al.|Journal of Clinical Oncology|2021

Cited by 1